Positive Rates of Preliminary Crossmatches Among Transplantation Candidates Waitlisted for Different Organs in the Korean Network for Organ Sharing

OBJECTIVE

For deceased-donor organ transplantations, negative T cell crossmatches (XMs) are mandatory for kidney and pancreas allocation in the Korean Network for Organ Sharing (KONOS) organ allocation system. Submission and periodic renewal of serum to the KONOS is required for all transplantation candidates of kidney or pancreas and these sera are distributed to 23 laboratories for preliminary XMs. We have investigated how sensitization status varies among transplantation candidates waitlisted for different organs.

METHODS

Positive rates of T cell XMs performed during recent 1-year period (from March 2014 to February 2015) in the Korea Organ Donation Agency laboratory have been analyzed according to different organs. For 163 cases of deceased donors, 3605 recipients (22.1 recipients per one donor) were crossmatched using both of National Institutes of Health and antihuman globulin complement-dependent cytotoxicity (CDC) methods and flow cytometry method.

RESULTS

T cell XM positive rates varied among transplantation candidates for different organs. The positive rate was high for kidney (485/3,145, 15.4%), and low for pancreas or kidney/pancreas (7/200, 3.5%), lung (0/41, 0%), and heart (11/221, 5.0%). Among XM-positive individuals, nearly two-thirds of the kidney transplantation candidates showed strong sensitization status with CDC+/flow+ results (64.5%), whereas pancreas or kidney/pancreas transplantation candidates more commonly showed weaker sensitization status with CDC-/flow+ results (85.7%).

CONCLUSION

Kidney transplantation candidates show a much higher positive rate and stronger sensitization status than candidates for other organs. The results of this study would be useful for determining the number of candidates to be crossmatched for different organs.

NELL-1 injection maintains long-bone quantity and quality in an ovariectomy-induced osteoporotic senile rat model

Over 10 million Americans have osteoporosis, and is the predominant cause of fractures in the elderly. Treatment of fractures in the setting of osteoporosis is complicated by a suboptimal bone regenerative response due to a decline in the number of osteoblasts, their function, and survival. Consequently, an osteogenic therapeutic to prevent and treat fractures in patients with osteoporosis is needed. Nel-like molecule-1 (NELL-1), a novel osteoinductive growth factor, has been shown to promote bone regeneration. In this study, we aim to demonstrate the capacity of recombinant NELL-1 to prevent ovariectomy (OVX)-induced osteoporosis in a senile rat model. Ten-month-old female Sprague-Dawley rats underwent either sham surgery or OVX. Subsequently, 50 μL of 600 μg/mL NELL-1 lyophilized onto a 0-50-μm tricalcium phosphate (TCP) carrier was injected into the femoral bone marrow cavity while phosphate-buffered saline (PBS) control was injected into the contralateral femur. Our microcomputed tomography results showed that OVX+PBS/TCP control femurs showed a continuous decrease in the bone volume (BV) and bone mineral density (BMD) from 2 to 8 weeks post-OVX. In contrast, OVX+NELL-1/TCP femurs showed resistance to OVX-induced bone resorption showing BV and BMD levels similar to that of SHAM femurs at 8 weeks post-OVX. Histology showed increased endosteal-woven bone, as well as decreased adipocytes in the bone marrow of NELL-1-treated femurs compared to control. NELL-1-treated femurs also showed increased immunostaining for bone differentiation markers osteopontin and osteocalcin. These findings were validated in vitro, in which addition of NELL-1 in OVX bone marrow stem cells resulted in increased osteogenic differentiation. Thus, NELL-1 effectively enhances in situ osteogenesis in the bone marrow, making it potentially useful in the prevention and treatment of osteoporotic fractures.

SU-E-T-234: LET Measurement Using Nuclear Emulsion and Monte Carlo Simulation for Proton Beam

PURPOSE

The significant issue of particle therapy such as proton and carbon ion biological effect on tumors and normal tissue. This effect closely connected with linear-energy-transfer (LET). This work presents a Monte Carlo study using GEANT4 and the verification using Nuclear Emulsion to show LET for proton beam.

METHODS

National Cancer Center (NCC) has IBA Beam Nozzle and cyclotron for proton therapy. We use proton beam bragg peak range 14cm. Also, we already developed the simulation using GEANT4 and finished validation for scattering proton beam. In our simulation, we make same condition with experimental setup.Nuclear emulsion films interleaved with tissue equivalent absorbers can be fruitfully used to reconstruct proton tracks with very high precision. This Nuclear emulsion film has been supported from Nagoya University, analyzed in Pusan University, was irradiated with a therapeutic proton beam at NCC. The Emulsion packs was located at entrance and bragg peak region of proton. This position means low and high LET region. The scanning of the emulsions has been performed at Nagoya University, where a fully automated microscopic scanning technology has been developed for the OPERA experiment on neutrino oscillations.

RESULTS

We could see the reconstructed track of proton scanning emulsion. From film scanning, we got the LET distribution at low and high LET region for several proton tracks. Simulation results was similar distribution within standard deviation in acceptance level. Also we got the RBE distribution using LET measurement for proton beam.

CONCLUSIONS

We measured LET at entrance and bragg peak region using Monte Carlo study and Nuclear Emulsion film, for NCC proton beam. This results means the good observation of LET using the nuclear emulsion. And this method can be used successfully in medical field.